Cresco Labs Records Q3 Revenues of $215.5 Million, Impairs $290.9 Million In Assets

Cresco Labs (CSE: CL) reported its third quarter financial results this morning, reporting marginal revenue growth to $215.5 million for the quarter. Most significantly, the company reported a substantial impairment loss, resulting in the firm reporting a net loss of $263.5 million.

Revenues for the third quarter improved slightly over the second quarter, climbing a modest 2.6% from $210.0 million to $215.5 million over the three month period. Gross profits however improved more significantly, climbing from $101.0 million to $108.3 million, representing a gross profit of 50.3%.

Operating expenses however eliminated any gains seen from a growing gross profit percentage, with total operating expenses amounting to $372.3 million, compared to $86.1 million in the prior quarter. The significant expense increase is the result of a $290.9 million impairment recorded by the company, related to the writedown of intangible assets due to a “strategic shift in California operations.”

The company as a result saw a loss from operations of $264.0 million. Losses were pushed further after an interest expense of $13.6 million, which was then offset by an income tax recovery of $12.4 million. The company overall posted a net loss of $263.5 million, while adjusted EBITDA came in at $56.4 million.

Cash and cash equivalents as of the quarter ended totaled out at $252.8 million, with the firm reporting other current assets of $196.2 million and total current liabilities of $209.2 million.

In terms of outlook, gross profit margins are expected to be in excess of 50.0% for the remainder of the year, while adjusted EBITDA is set to hit 30.0% by the end of the year. Fourth quarter revenue has also been guided to be between $235 million and $245 million.

Cresco Labs last traded at $10.95 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Cresco Labs to Sell Illinois Properties in Leaseback Arrangement

Cresco Labs (CSE: CL) announced this morning that it would be entering a sale and...

Friday, September 27, 2019, 09:07:51 AM

Cresco Labs To Acquire Pennsylvania Operator Laurel Harvest For US$80 Million

Cresco Labs (CSE: CL) reported on Thursday the execution of an agreement to acquire 100%...

Friday, October 15, 2021, 10:56:00 AM

P Diddy To Spend $185 Million Acquiring Cannabis Assets From Cresco Labs, Columbia Care

Cresco Labs (CSE: CL) appears to be monetizing the appointment of director Tarik Brooks, which...

Friday, November 4, 2022, 08:44:11 AM

Cannabis Earnings: Cantor Fitzgerald Adjusts Ratings Ahead Of Earnings

Last week, Pablo Zuanic from Cantor Fitzgerald released his second-quarter estimates and updated his 12-month...

Wednesday, August 11, 2021, 09:56:00 AM

Cresco Labs Finalizes Acquisition of Hope Heal Health

Cresco Labs (CSE:CL), has received change in ownership approval from the Massachusetts Cannabis Control Commission,...

Friday, February 7, 2020, 09:42:52 AM